Skip to main content
Journal cover image

CTNI-68. FIREFLY-1 (PNOC026): Phase 2 study of pan-RAF inhibitor tovorafenib in pediatric and young adult patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors.

Publication ,  Conference
Kilburn, L; Landi, D; Leary, S; Ziegler, D; Baxter, P; Franson, A; McCowage, G; Waanders, A; Van Der Lugt, J; Oren, M; Gerber, N; Gottardo, N ...
Published in: Neuro-Oncology
November 14, 2022

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Neuro-Oncology

DOI

ISSN

1522-8517

Publication Date

November 14, 2022

Volume

24

Issue

7

Start / End Page

vii89 / vii89

Location

Tampa Convention Center, Tampa Bay, FL

Publisher

Oxford University Press

Conference Name

2022 Society for Neuro-Oncology’s 27th Annual Scientific Meeting and Education Day

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1109 Neurosciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kilburn, L., Landi, D., Leary, S., Ziegler, D., Baxter, P., Franson, A., … Hansford, J. (2022). CTNI-68. FIREFLY-1 (PNOC026): Phase 2 study of pan-RAF inhibitor tovorafenib in pediatric and young adult patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors. In Neuro-Oncology (Vol. 24, pp. vii89–vii89). Tampa Convention Center, Tampa Bay, FL: Oxford University Press. https://doi.org/10.1093/neuonc/noac209.333
Kilburn, Lindsay, Daniel Landi, Sarah Leary, David Ziegler, Patricia Baxter, Andrea Franson, Geoffrey McCowage, et al. “CTNI-68. FIREFLY-1 (PNOC026): Phase 2 study of pan-RAF inhibitor tovorafenib in pediatric and young adult patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors.” In Neuro-Oncology, 24:vii89–vii89. Oxford University Press, 2022. https://doi.org/10.1093/neuonc/noac209.333.
Kilburn L, Landi D, Leary S, Ziegler D, Baxter P, Franson A, et al. CTNI-68. FIREFLY-1 (PNOC026): Phase 2 study of pan-RAF inhibitor tovorafenib in pediatric and young adult patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors. In: Neuro-Oncology. Oxford University Press; 2022. p. vii89–vii89.
Kilburn, Lindsay, et al. “CTNI-68. FIREFLY-1 (PNOC026): Phase 2 study of pan-RAF inhibitor tovorafenib in pediatric and young adult patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors.Neuro-Oncology, vol. 24, no. 7, Oxford University Press, 2022, pp. vii89–vii89. Manual, doi:10.1093/neuonc/noac209.333.
Kilburn L, Landi D, Leary S, Ziegler D, Baxter P, Franson A, McCowage G, Waanders A, Van Der Lugt J, Oren M, Gerber N, Gottardo N, Khuong-Quang D-A, Nysom K, Bailey S, Driever P, Perreault S, Witt O, Hahn S, Hargrave D, Hassall T, Nada J, Jin Kang H, Larouche V, Toledano H, Cassie K, Abdelbaki M, Chi S, Gardner S, Whipple N, Mueller S, Blackman S, Zhao X, Da Costa D, Cox M, Packer R, Hansford J. CTNI-68. FIREFLY-1 (PNOC026): Phase 2 study of pan-RAF inhibitor tovorafenib in pediatric and young adult patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors. Neuro-Oncology. Oxford University Press; 2022. p. vii89–vii89.
Journal cover image

Published In

Neuro-Oncology

DOI

ISSN

1522-8517

Publication Date

November 14, 2022

Volume

24

Issue

7

Start / End Page

vii89 / vii89

Location

Tampa Convention Center, Tampa Bay, FL

Publisher

Oxford University Press

Conference Name

2022 Society for Neuro-Oncology’s 27th Annual Scientific Meeting and Education Day

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1109 Neurosciences